The global orthopedic bone cement market size is expected to reach USD 975.7 million by 2030, and is projected to register a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as rising demand for minimally invasive procedures, advancements in casting materials and techniques, and the growing prevalence of orthopedic disorders and injuries drive the market's growth. For instance, according to a study published by the Institute for Health Metrics and Evaluation in August 2023, osteoarthritis affects 15% of the global population over the age of 30.
Furthermore, the rise in bone fracture cases boosts the demand for orthopedic bone cement products. For instance, according to the World Osteoporosis Day Survey 2023 conducted by the International Osteoporosis Foundation, 43% of the surveyed women reported that they had broken a bone following a bump or a minor fall after age 50. In addition, according to an article published by ScienceDirect in June 2023, the prevalence of hip fractures in India is estimated to be more than 120 fractures per 100,000 individuals aged over 50 annually.
Manufacturers have launched antibiotic-loaded cement that reduces the chances of post-surgical infections, particularly in total joint arthroplasty. Advancements in end-use technology are expected to boost the adoption of orthopedic bone cement among surgeons. Furthermore, the rising aging population is crucial in fueling the demand for bone cement. The geriatric population is at a higher risk of fractures and related injuries and frequently needs joint replacement procedures. This cement provides a better alternative to wires and screws, which can create discomfort for the patients.
Some of the key players in the market are Stryker, Zimmer Biomet, DePuy Synthes, Smith & Nephew, DJO Global Inc. (Enovis), Arthrex Inc., Tecres S.p.A. (Demetra Holding S.p.A.), Heraeus Medical LLC, and Cardinal Health. Players are adopting key strategic initiatives to expand their business footprint and grow their clientele. For instance, in July 2022, GRAFTYS SA, a manufacturer of resorbable bone cement, raised funding of USD 2.20 million from its existing shareholders to accelerate commercial advancement and the introduction of new products.
Request a free sample copy or view report summary: Orthopedic Bone Cement Market Report
Based on material, the polymethyl methacrylate (PMMA) segment dominated the market in 2023 with the largest revenue share. Bone cement, consisting of PMMA, is a bioinert material used for prosthesis fixation in joint arthroplasty.
Based on product, the antibiotic-loaded bone cement segment dominated the market in 2023. Antibiotic-loaded cement helps improve implant fixation and reduce the deep surgical site infection rate following hemiarthroplasty.
Based on end-use, the hospitals segment dominated the market in 2023, owing to their dominance in developing and low-income nations, as many patients visit the hospitals.
North America dominated the global market due to government initiatives to accelerate research activities for orthopedic conditions, the presence of many market players, and the launch of a diverse range of products.
Grand View Research has segmented the global orthopedic bone cement market based on material, product, end-use, and region:
Orthopedic Bone Cement Material Outlook (Revenue, USD Million, 2018 - 2030)
Polymethyl Methacrylate (PMMA)
Calcium Phosphate
Glass Polyalkeonate
Orthopedic Bone Cement Product Outlook (Revenue, USD Million, 2018 - 2030)
Bone Cement Without Antibiotics
Antibiotic Loaded Bone Cement
Orthopedic Bone Cement End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Outpatient Facilities
Orthopedic Bone Cement Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
Spain
Italy
France
Denmark
Norway
Sweden
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Orthopedic Bone Cement Market
Stryker
Zimmer Biomet
DePuy Synthes
Smith & Nephew
DJO Global Inc. (Enovis)
Arthrex Inc.
Tecres S.p.A. (Demetra Holding S.p.A.)
Heraeus Medical GmbH
Cardinal Health
"The quality of research they have done for us has been excellent..."